Comparative Safety Profiles of Baricitinib and Tofacitinib in the Treatment of Adult Alopecia Areata: A Pharmacovigilance Study Based on the FAERS Database
January 2026
in “
Frontiers in Public Health
”
Studysummary This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on public-pages-files-2025.frontiersin.org →